Apellis Pharmaceuticals shares plummeted on Friday after the European Medicines Agency (EMA) rejected its drug pegcetacoplan for treating geographic atrophy, a form of age-related macular degeneration. The EMA’s decision comes despite support from the European retina community and dissenting votes from some members of the committee.